Analyst Conference Summaries

Biotechnology Investor Aids

Reata Pharmaceuticals

conference date: March 2, 2018 press release only

Reata Pharmaceuticals a Buy [pay wall; Feb. 14, 2018 at Seeking Alpha]

March 2, 2018

Reata Pharmaceuticals (RETA) is a clinical-stage biotechnology company specializing in therapies to improve mitochondrial functions for rate diseases, including chronic kidney diseases.

Reata Pharmaceutical web site



More Analyst Conference Pages:


Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2018 William P. Meyers